Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease-Reference-Cited by-同舟云学术

Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease

Published:2021 Issue:1 Volume:17 Page:36
ISSN:2752-5465
Container-title:Neurology
language:en
Short-container-title:

Author:

Isaacson Stuart H,Lyons Kelly E,Amjad Fahd,Pahwa Rajesh, , , ,

Abstract

Funder

This article is published under the Creative Commons Attribution Non-commercial License.

Publisher

Touch Medical Media, Ltd.

Reference89 articles.

1. Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27:27–42.

2. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–53.

3. Lewin Group. Economic Burden and Future Impact of Parkinson’s Disease. 2019. Available at: michaeljfox.org/sites/default/files/media/document/2019%20Parkinson%27s%20Economic%20Burden%20Study%20-%20FINAL.pdf (accessed 3 May 2021).

4. Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America.NPJ Parkinsons Dis. 2018;4:21.

5. DeMaagd G, Philip A. Parkinson’s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis.P T. 2015;40:504–32.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amantadine extended release capsules (GOCOVRI®) in Parkinson’s disease: a profile of its use in the USA;Drugs & Therapy Perspectives;2022-05